IHL.AX लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (17 Nov 2023 @ 10:40):

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia...

Stats
आज की मात्रा	61.36M
औसत मात्रा	6.43M
बाजार मूल्य	65.07M
EPS	$0 ( 2024-02-25 )
अगली कमाई की तारीख	( $0 ) 2024-07-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0315
ATR14	$0.00600 (14.63%)

मात्रा सहसंबंध

लंबा: -0.16 (neutral)

छोटा: 0.00 (neutral)

Signal:(30.519) Neutral

Incannex Healthcare Ltd सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Incannex Healthcare Ltd सहसंबंध - मुद्रा/वस्त्र

-0.22
( neutral )

-0.26
( neutral )

0.00
( neutral )

-0.68
( moderate negative )

-0.46
( neutral )

0.38
( neutral )

Incannex Healthcare Ltd वित्तीय

Annual	2022
राजस्व:	$1.01M
सकल लाभ:	$1.01M (100.00 %)
EPS:	$-0.0130

FY	2022
राजस्व:	$1.01M
सकल लाभ:	$1.01M (100.00 %)
EPS:	$-0.0130

FY	2023
राजस्व:	$0
सकल लाभ:	$0 (0.00 %)
EPS:	$0

FY	2022
राजस्व:	$0
सकल लाभ:	$-6 338.00 (0.00 %)
EPS:	$-0.00700

Financial Reports:

No articles found.

Incannex Healthcare Ltd

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. It offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. The company also develops IHL-42X, which has completed Phase IIa clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury/concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Melbourne, Australia.